Proactive Investors - Run By Investors For Investors

Ventripoint Diagnostics reports progress for latest VMS +3.0 heart monitoring system

VMS is a machine, which revolutionizes the way doctors treat heart patients as it can give accurate and rapid volumetric information about all four chambers of the heart
heart in hand
Usability studies are underway at two leading Canadian hospitals to establish the effectiveness and ease of use of the VMS +3.0

Ventripoint Diagnostics Ltd (CVE:VPT) (OTCQB:VPTDF) announced Tuesday that the development stage for its next-generation VMS +3.0 heart-monitoring system is nearing completion.

Usability studies are now underway at a pair of leading Canadian hospitals to establish the effectiveness and ease of use of VMS +3.0 and the Toronto-based company will seek regulatory approval in North America and Europe as soon as these studies are finished.

READ: VentriPoint Diagnostics eyeing big opportunity after winning first US customer for VMS plus

VMS is a machine, which revolutionizes the way doctors treat heart patients as it can give accurate and rapid volumetric information about all four chambers of the heart.

It is the only technology in the world that can perform such an analysis of all four chambers using data from a conventional 2D (two dimensional) eco-cardiogram (in other words an ultrasound test).

Ventripoint's latest system uses sensor technology, which allows for patients to move during the imaging portion of the exam, and it is compact and portable enough that it can be set up within minutes.

READ: VentriPoint Diagnostics shares nudge higher as it updates on sales efforts

“Replacing the old magnetic tracking system with our new tracking sensor technology enables patient repositioning during the examination,” said George Adams, CEO of Ventripoint. “This feature eliminates the usual restrictions on the person being scanned and will be instrumental in the ease of use by clinicians for both children and adults.”

Ventripoint is also developing a workstation version of the VMS + 3.0 software, which allows for the analysis of echocardiograms in a reading room elsewhere in the hospital. This will permit sonographers to continue to scan new patients, while studies are analyzed by cardiologists.

Ventripoint shares held steady at C$0.16 in morning trade on Tuesday.

Contact Ellen Kelleher at [email protected]

View full VPT profile View Profile

VentriPoint Diagnostics Ltd. Timeline

Related Articles

test tubes
May 07 2019
Here we take a closer look at Arix Biosciences PLC (LON:ARIX), a listed venture capital company that doesn’t appear to be receiving the recognition it deserves
LX2 analyzer
May 07 2019
Armed with promising study results and proven technology, LexaGene is getting ready to launch the LX2 Genetic Analyzer to underserved markets valued at an estimated US$40 billion
healthy gut
Mon
Here we take a look at AIM-listed life sciences group, OptiBiotix Health
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use